Patrick G Enright
CIK 1253886 · last filed 2026-09-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
JAZZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
800 EL CAMINO REAL, SUITE 220
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JAZZ | Director | 21,278 | $205.70 | $4.38M | -$228.70M | 67 | 2026-09-02 |
| ZBIO | Director | 1,844,659 | $27.24 | $50.25M | $9.73M | 4 | 2026-06-17 |
| BIOA | Director | 1,310,589 | $4.99 | $6.54M | $7.20M | 3 | 2026-06-12 |
| VERA | Director | 3,602,475 | $28.30 | $101.95M | $32.53M | 11 | 2026-05-26 |
| MANE | Director | 2,407,752 | $137.39 | $330.80M | $18.27M | 1 | 2026-02-05 |
| Aptinyx Inc. (APTX) Delisted | Director | 3,451,746 | $0.06 | $210.6K | $3.19M | 14 | 2022-05-31 |
| Sierra Oncology, Inc. (SRRA) Delisted | 10%+ Owner | 5,611 | $54.99 | $308.5K | $0 | 1 | 2022-04-29 |
| Eargo, Inc. (EAR) Delisted | 10%+ Owner | 195,935 | $2.57 | $503.6K | $12.60M | 1 | 2020-10-22 |
| COLL | Director | 0 | $23.21 | $0 | $1.92M | 11 | 2020-10-14 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 2,007,225 | $4.00 | $8.03M | $40.00M | 1 | 2020-07-28 |
| 89bio, Inc. (ETNB) Delisted | 10%+ Owner | 2,600,877 | $14.84 | $38.60M | $48.80M | 2 | 2020-07-14 |
| Molecular Templates, Inc. (MTEM) Delisted | 10%+ Owner | 279,902 | $0.00 | $28 | $29.98M | 1 | 2019-11-27 |
| AXNX | 10%+ Owner | 1,173,333 | $0.76 | $891.7K | $24.00M | 1 | 2018-11-02 |
| KALA | 10%+ Owner | 823 | $0.19 | $153 | $12.90M | 1 | 2017-07-27 |
| CORT | Director | 5,993,653 | $87.12 | $522.20M | -$43.10M | 26 | 2017-03-20 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | Director | 7,467,694 | — | — | $10.45M | 3 | 2016-03-31 |
| Esperion Therapeutics, Inc. (ESPR) Delisted | Director | 1,119,256 | $3.18 | $3.56M | -$69.15M | 6 | 2015-05-18 |
Recent Filings · Page 2 of 16
157 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-10-14 | ZBIO | Buy (P) | +117,255 | $2.25M | EDGAR |
| 2025-08-11 | JAZZ | Mixed | +1,702 | -$200.8K | EDGAR |
| 2025-08-08 | JAZZ | Notice (144) | −3,731 | -$417.9K | EDGAR |
| 2025-06-25 | VERA | Buy (P) | +250,000 | $5.28M | EDGAR |
| 2025-06-12 | ZBIO | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | BIOA | Grant (A) | — | $0 | EDGAR |
| 2025-05-16 | VERA | Grant (A) | — | $0 | EDGAR |
| 2024-09-27 | BIOA | Mixed | +1,710,589 | $7.20M | EDGAR |
| 2024-09-16 | ZBIO | Mixed | +2,501,934 | $7.48M | EDGAR |
| 2024-08-06 | JAZZ | Grant (A) | +3,731 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.